Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.47 |
| ▸ | RXRB | P28702 | 3/20 | 0.47 |
| ▸ | RXRG | P48443 | 3/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29921217 | 1.00 | RXRA (0.47) | RXRARXRBRXRGMRGPRX4PTGER1 | |
| SCHEMBL29921162 | 0.89 | RXRA (0.47) | RXRARXRBRXRGMRGPRX4PTGER1 | |
| SCHEMBL23834854 | 0.89 | RXRA (0.47) | RXRARXRBRXRGMRGPRX4PTGER1 | |
| SCHEMBL30822044 | 0.79 | RXRA (0.55) | RXRARXRBRXRGMRGPRX4PTGER1 | |
| SCHEMBL23835130 | 0.78 | RAB9A (0.53) | RXRARXRBRXRGMRGPRX4PTGER1 | |
| SCHEMBL23835283 | 0.78 | MAPK14 (0.43) | RXRARXRBMRGPRX4PTGER1RAB9A | |
| SCHEMBL29921371 | 0.78 | MAPK14 (0.43) | RXRARXRBMRGPRX4PTGER1RAB9A | |
| SCHEMBL20482946 | 0.77 | RXRA (0.52) | RXRARXRBRXRGMRGPRX4PTGER1 | |
| SCHEMBL23834851 | 0.76 | RXRA (0.42) | RXRARXRBRXRGMRGPRX4PTGER1 | |
| SCHEMBL29921189 | 0.76 | RXRA (0.42) | RXRARXRBRXRGMRGPRX4PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121421-B1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20240382457-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS PHARMA AG (CH) | 2024-11-21 | — | — | US | disclosed |
| US-12083101-B2 | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| EP-4121421-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | Novartis AG (CH) | 2023-01-25 | — | — | EP | disclosed |
| US-20210299100-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS PHARMA AG (CH) | 2021-09-30 | — | — | US | disclosed |
| WO-2021186324-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021186324-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083101-B2 | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | YAP1, TEAD3, TEAD2 | RXRA 2234/4885RXRB 2037/4885RXRG 2706/4885 |
| US-20240382457-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | YAP1, TEAD3, TEAD2 | RXRA 2234/4885RXRB 2037/4885RXRG 2706/4885 |
| US-20210299100-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | YAP1, TEAD3, TEAD2 | RXRA 2301/4885RXRB 2091/4885RXRG 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.